1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

  • May 2015
  • 69 pages
  • ID: 3002300
  • Format: PDF
  • By Frost & Sullivan

Summary

Table of Contents

Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics

This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.

Executive Summary—Key Findings
- The ACS therapeutics market is comprised of both branded and generics drugs, the latter of which registers the most revenue.
- The market is driven by the ageing population and a prevalence of conditions associated with unhealthy living such as obesity and metabolic disorders such as diabetes.
- There are approximately key marketed branded drugs and hundreds of generics indicated for the treatment of ACS. The current treatments increasingly focus on targeting novel orphan pathways for treatment of ACS and to augment the existing class of therapeutics.
- These new drug classes are being evaluated to merge various unmet gaps among patients such as statin intolerance, bleeding risks associated with existing blood thinning drugs, and an effective treatment of atherosclerotic plaques.
- Among the various classes of ACS therapeutics, anti-hypertensives and cholesterol lowering drugs are currently dominating the ACS therapeutics market with an influx of new drugs targeting novel pathways.
The key drug targets include the proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP).
- The next 5 years are expected to witness the launch of the key drugs Losmapimod (GSK), Praluent (Sanofi & Regeneron), Anacetrapib (Merck & Co.), Evacetrapib (Eli Lilly and Co.), and Evolocumab (Amgen), which will boost market share for branded drugs to approximately %.
o Losmapimod from GSK’s drug portfolio is an anti-inflammatory drug which inhibits the p38 mitogen activated protein kinase (MAPK) and is being evaluated in Phase clinical trials (LATITUDE-TIMI 60).
o Amgen’s Repatha (Evolocumab) Phase 3 clinical trial program PROFICIO has engaged patients for testing the LDL-C and cardiovascular outcomes following inhibition of PCSK9 in different populations. Nearly 10 clinical phase trials are being conducted under this Phase 3 trial program.
- The drug was designed to inhibit PCSK9 from binding to LDL receptors on the liver’s surface. In the absence of PCSK9, enough LDL receptors will not be present on the surface of the liver to remove LDL-C from the blood.
o GSK has so far recruited patients for this trials to evaluate the safety of the drug in reducing the risk of cardiovascular events such as death, heart attack, or near heart attack that require urgent treatment. The enzyme p38 kinase is known for its role in inflammation and its inhibition is expected to stabilize atherosclerotic plaques and reduce plaque rupture thereby preventing thrombosis.
o The drug Evolocumab combined with the standard care treatment benefitted the patients by reducing the LDL-c by % when compared to standard of care treatment alone.
o Sanofi and Regeneron has recently received a priority review certificate for its lead drug Praluent (alirocumab) an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). So far, ten Phase 3 clinical trials, including ODYSSEY OUTCOMES, will include over patients.
o Anacetrapib is being developed by Merck for treatment of hypercholesterolemia and prevention of cardiovascular disease. It has engaged over 30,000 participants in a randomized double-blinded, placebo-controlled trial code named REVEAL and DEFINE Phase 3 trials. The drug is a CETP inhibitor.
- The market size of the ACS therapeutics was approximately $ billion in 2014 and is expected to reach $ billion in 2019 growing at a CAGR of %.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline ...

Dyslipidemia Global Clinical Trials Review, H2, 2019

Dyslipidemia Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Dyslipidemia Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2019" provides an overview of Dyslipidemia clinical trials scenario.This ...

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on